Aside the current lack of specificity and similarity of effects of the first generation of MASTL inhibitors, its combination with genotoxic treatment, the titration of the drug in parallel to the evaluation of the degree of inhibition of MASTL, especially in breast cancer overexpressing MASTL, will need to be investigated in the future [19, 21]. This evidence concerns the gene MASTL and breast cancer.